Upcoming conferences

Schedule a meeting with our drug development and manufacturing experts at AAPS & CPhI this November

How do I accelerate my drug development program?

Quotient is your answer.

Translational Pharmaceutics

Quotient Sciences’ Translational Pharmaceutics® platform innovates the way you design and implement your drug development program. It offers you integrated formulation development, real-time adaptive GMP manufacturing and clinical research capabilities proven to reduce drug development costs and shorten timelines.

Translational Pharmaceutics transforms the traditional approach of outsourcing development work to separate contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) – simplifying and streamlining your outsourcing and program management.

Our team works with you to design a customized solution to accelerate both your simple and complex early drug development programs.

We offer expert medical and scientific assessment of your objectives and interpretation of your data. Quotient supports you with flexible, adaptive solutions addressing critical steps in your drug development process:

  • How do I accelerate my molecule to Proof-of-Concept?
  • How do I optimize my formulation?
  • How can I simplify the delivery of my human ADME study?

The benefits of Translational Pharmaceutics

When you need to quickly identify your opportunity and design the best quality solution, Quotient is your answer.

  • Reduces timelines

    by six months or more

  • Delivers cost savings

    in excess of $500,000

  • Conserves drug substance

    by more than 85%

  • Real-time decision-making

    Facilitates real-time decision making based on emerging human clinical data

  • Provides flexibility

    to adjust formulation composition within a study

  • Streamlines

    vendor management

Reduce time with Translational Pharmaceutics

Results have proved that you can gain up to 6 months from lab to clinic comparing to a conventional approach.

  • 9-12


    Conventional approach

  • 3-4


    Quotient Sciences' approach


Formulation & process development

Formulation & process development


Transfer to GMP

IMPD submission


Process development & verification

CT manufacture & release


Stability study



IMPD Submission


CT manufacture & release


Ship to clinical site



Overcome your drug delivery challenges

With Translational Pharmaceutics, our scientists help you overcome the drug delivery challenges presented by your molecule for all dosage forms and routes of delivery.

Dosage Forms

  • Solids (tablets, capsules, multiparticulates)
  • Non-sterile liquids (solutions and suspensions)
  • Semi-solids (creams, oil, gels, ointments)
  • Inhalation (DPI/MDI/nebulizers)
  • Parenterals (solutions)

Routes of Delivery

  • Oral 
  • Inhaled, pulmonary, nasal
  • Topical
  • Parenteral (subcutaneous, intravenous)

Using our Translational Pharmaceutics approach, you can streamline your management of outsourced partners. Your program will be led by a single project manager who will manage an integrated cross-functional project team focused on delivering all of the components of traditional CDMO and CRO services — allowing you to capture multiple efficiencies.

What is it like to work with Quotient?

Here's what some of our customers said:

“The company’s ability to integrate manufacturing and dosing really accelerated the conduct of the study and was one of the main reasons that Corcept selected Quotient to undertake the study.”

Hazel Hunt

Vice President of Research at Corcept

01 / 04

“After taking everything into account — the manufacturing costs of a traditional CMO model, creating multiple lots of material that may never get used, etc. — the Translational Pharmaceutics approach was a cost-effective option, especially when we took the additional cost of time saved into consideration.”

Deborah Gouveia

VP Program and Alliance Management, Stealth BioTherapeutics

02 / 04

“Having an integrated way of working is truly innovative and offers a company like Clovis a really efficient option. The entire study was a very positive experience.”

Gillian C. Ivers-Read

Executive Vice President, Technical Operations and Chief Regulatory Officer and co-founder of Clovis

03 / 04

“The understanding we have gained through working with Quotient — in terms of both the formulation development and the manufacturing — will be invaluable.”

Dr David Hava

Chief Scientific Officer at Pulmatrix Inc.

04 / 04

Ask us a question